Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

25.24B

Market cap25.24B

Price-Earnings ratio

16.18

Price-Earnings ratio16.18

Dividend yield

—

Dividend yield—

Average volume

1.66M

Average volume1.66M

High today

$128.17

High today$128.17

Low today

$123.89

Low today$123.89

Open price

$127.51

Open price$127.51

Volume

664.46K

Volume664.46K

52 Week high

$132.60

52 Week high$132.60

52 Week low

$81.09

52 Week low$81.09

Stock Snapshot

The current Incyte(INCY) stock price is $124.51, with a market capitalization of 25.24B. The stock trades at a price-to-earnings (P/E) ratio of 16.18.

On 2026-09-23, Incyte(INCY) stock traded between a low of $123.89 and a high of $128.17. Shares are currently priced at $124.51, which is +0.5% above the low and -2.9% below the high.

The Incyte(INCY)'s current trading volume is 664.46K, compared to an average daily volume of 1.66M.

During the past year, Incyte(INCY) stock moved between $81.09 at its lowest and $132.60 at its peak.

INCY News

Barron's 13h

Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch - Barron's

...

TipRanks 3d

Specialised Therapeutics expands partnership with Incyte to include Opzelura

Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its existing partnership with Incyte (INCY) Biosciences International,...

Nasdaq 4d

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the...

Analyst ratings

52%

of 31 ratings

Buy

41.9%

Hold

51.6%

Sell

6.5%

More INCY News

Simply Wall St 4d

Does Earlier MINJUVI Access Change The Bull Case For Incyte?

Incyte reported that MINJUVI, a humanized anti CD19 antibody used with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, is now funded...

TipRanks 4d

AFLAC, CME, Incyte, Box, Five Below Insider Shake-Up

Insiders have been trading these 5 stocks: ((AFL)), ((CME)), ((INCY)), ((BOX)) and ((FIVE)). Here is a breakdown of their recent trades and their value. Japan...

Simply Wall St 5d

Incyte Looks Fully Valued As Ontario Backs MINJUVI Access

Incyte (INCY) is back on investor radar after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eli...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.